Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025

View Full Press Release
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)